Literature DB >> 11513838

Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile.

A W Schmidt1, L A Lebel, H R Howard, S H Zorn.   

Abstract

Ziprasidone is a novel antipsychotic agent with a unique combination of pharmacological activities at human receptors. Ziprasidone has high affinity for human 5-HT receptors and for human dopamine D(2) receptors. Ziprasidone is a 5-HT(1A) receptor agonist and an antagonist at 5-HT(2A), 5-HT(2C) and 5-HT(1B/1D) receptors. Additionally, ziprasidone inhibits neuronal uptake of 5-HT and norepinephrine comparable to the antidepressant imipramine. This unique pharmacological profile of ziprasidone may be related to its clinical effectiveness as a treatment for the positive, negative and affective symptoms of schizophrenia with a low propensity for extrapyramidal side effects, cognitive deficits and weight gain.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11513838     DOI： 10.1016/s0014-2999(01)01188-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  56 in total

1.  The lack of effect of ziprasidone on platelet serotonin concentration in schizophrenic patients.

Authors:  Marina Sagud; Matea Nikolac; Alma Mihaljevic-Peles; Gordana Nedic; Bjanka Vuksan Cusa; Maja Mustapic; Miro Jakovljevic; Dorotea Muck-Seler; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2011-10-12       Impact factor: 4.530

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Quantitative analysis of the effects of some "atypical" and "conventional" antipsychotics on progressive ratio schedule performance.

Authors:  Z Zhang; J F Rickard; K Asgari; S Body; C M Bradshaw; E Szabadi
Journal:  Psychopharmacology (Berl)       Date:  2004-11-25       Impact factor: 4.530

4.  Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.

Authors:  Anil Purohit; Carol Smith; Katharine Herrick-Davis; Milt Teitler
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

Review 5.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

6.  The effects of ziprasidone on regional c-Fos expression in the rat forebrain.

Authors:  C A Jennings; J E Cluderay; J Gartlon; J Cilia; A Lloyd; D N C Jones; E Southam
Journal:  Psychopharmacology (Berl)       Date:  2005-12-03       Impact factor: 4.530

7.  Ziprasidone therapy for post-traumatic stress disorder.

Authors:  Zakaria Siddiqui; William A Marcil; Subhash C Bhatia; Sriram Ramaswamy; Frederick Petty
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

8.  Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease.

Authors:  Alan L Berkowitz
Journal:  Psychiatry (Edgmont)       Date:  2006-11

Review 9.  Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.

Authors:  Dennis H Kim; Matthew J Maneen; Stephen M Stahl
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 10.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.